Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunotherapy
Biotech
BMS-backed Dispatch unveils with $216M, Carl June as cofounder
Dispatch's two-pronged approach has clearly impressed investors. Since 2022, the biotech has raised $216 million in both seed and series A money.
Gabrielle Masson
Jul 23, 2025 6:30am
Hookipa, having sold off vaccines to Gilead, opts to wind down
Jul 21, 2025 3:15am
BioNTech's chief strategy officer heads for the exit
Jul 17, 2025 10:55am
Biopsies illuminate potential of Candel's prostate cancer drug
May 22, 2025 6:57pm
BioNTech makes £1B commitment to expand UK research, build HQ
May 20, 2025 11:15am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
